Fig. 2: sBCMA limits in vitro efficacy of anti-BCMA immunotherapies. | Leukemia

Fig. 2: sBCMA limits in vitro efficacy of anti-BCMA immunotherapies.

From: Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Fig. 2

A IL-2 (pg/mL) and B IFN-γ (pg/mL) levels were quantified by ELISA from co-culture supernatants after 20 h of incubation using ELISA MAX Deluxe Set for human IL-2 (431816, BioLegend) and human IFN-γ (430116, BioLegend). C Cytotoxic activity of belamaf was assessed in the presence of sBCMA using a luminescence-based viability assay with PBS as solvent control (**P < 0.005, ***P < 0.001, ****P < 0.0001). Abbreviations: IL-2 interleukin-2, IFN-γ interferon-gamma, cilta-cel ciltacabtagene autoleucel, BCMA B-cell maturation antigen, CAR chimeric antigen receptor, belamaf belantamab-mafodotin, solv. Ctr solvent control.

Back to article page